Welcome to our dedicated page for Ironwood Pharmaceuticals news (Ticker: IRWD), a resource for investors and traders seeking the latest updates and insights on Ironwood Pharmaceuticals stock.
Ironwood Pharmaceuticals, Inc. develops and commercializes therapies for gastrointestinal and rare diseases. Company news centers on LINZESS® (linaclotide), its commercial product for irritable bowel syndrome with constipation and chronic idiopathic constipation, including prescription demand, U.S. net sales, label-related regulatory updates, and pediatric functional constipation data.
Recurring updates also cover apraglutide, an investigational next-generation, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients dependent on parenteral support. Ironwood announcements frequently include quarterly results, financial guidance, cash flow and debt commentary, medical meeting presentations, and investor communications tied to its GI-focused research and commercialization strategy.
Ironwood Pharmaceuticals (IRWD) will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10 at 10:15 a.m. ET.
A live webcast and post-event replay of the session will be available through the Investors & Media section of Ironwood’s website, www.ironwoodpharma.com.
Ironwood Pharmaceuticals (Nasdaq: IRWD) reported strong Q2 2026 results and raised full-year 2026 guidance. LINZESS U.S. net sales guidance increased to $1.15–$1.20 billion, implying >30% year-over-year growth. Total revenue guidance rose to $460–$485 million and adjusted EBITDA guidance to >$310 million.
Q2 2026 LINZESS U.S. net sales were $282.3 million (14% YoY), with collaboration revenue to Ironwood of $110.0 million (28% YoY). Total revenue was $113.0 million, GAAP net income $51.3 million and adjusted EBITDA $83.0 million. Ironwood repaid $200 million of convertible notes using cash on hand and ended the quarter with $79.1 million in cash and $385.0 million drawn on its revolving credit facility. The FDA approved LINZESS for pediatric functional constipation in May 2026, and the confirmatory Phase 3 STARS-2 trial of apraglutide in SBS-IF is now actively recruiting patients.
Ironwood Pharmaceuticals (Nasdaq: IRWD) announced it will host its second quarter 2026 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 6, 2026. U.S. participants can dial (888) 596-4144 and international callers (646) 968-2525, using conference ID and event passcode 3647053.
The live webcast and subsequent replay will be available in the Investors & Media section of Ironwood’s website. A telephone replay will run from approximately 11:30 a.m. ET on August 6, 2026 through 11:59 p.m. ET on August 20, 2026 at (800) 770-2030 with conference ID 3647053.
Ironwood Pharmaceuticals (Nasdaq: IRWD) announced that Chief Medical Officer and Head of Research and Drug Development Dr. Michael Shetzline will retire after a 30-year career, and that Dr. Jeffrey Silber has been appointed his successor, effective July 20, 2026. Dr. Silber will lead Research and Drug Development, Regulatory Affairs and Medical Affairs, reporting to CEO Tom McCourt, while Dr. Shetzline remains as an advisor to support a smooth transition.
Ironwood also reported that the confirmatory Phase 3 STARS-2 trial of apraglutide in patients with short bowel syndrome with intestinal failure (SBS-IF) was initiated in June and is now actively recruiting. According to the company, Dr. Silber brings extensive drug development and GI-focused experience from Vedanta Biosciences, EMD Serono/Merck KGaA, AbbVie and Merck & Co.
Ironwood Pharmaceuticals (Nasdaq: IRWD) announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 4 at 11:05 a.m. ET.
A live webcast and subsequent replay will be available via the Investors & Media section of Ironwood’s website.
Ironwood Pharmaceuticals (Nasdaq: IRWD) announced that the FDA has approved LINZESS (linaclotide) for pediatric patients 2 years of age and older with functional constipation (FC), expanding its prior approval from 6+ years. LINZESS remains the only FDA‑approved prescription therapy for pediatric FC and received priority review for this indication.
The new approval is supported by a 12‑week Phase 3 randomized, placebo‑controlled trial in children aged 2‑5, where LINZESS 72 mcg improved spontaneous bowel movement frequency versus placebo, with a safety profile generally consistent with adult and older pediatric trials.
Ironwood Pharmaceuticals (Nasdaq: IRWD) reported Q1 2026 results: LINZESS U.S. net sales $272.5M (+97% YoY) and total revenue $106.5M. GAAP net income was $40.8M; adjusted EBITDA $76.7M. FDA granted priority review for LINZESS sNDA (PDUFA May 24, 2026). Apraglutide Phase 3 STARS-2 site initiations expected Q2 2026. Cash $220.5M; revolver balance $385.0M. 2026 guidance: U.S. LINZESS net sales $1.125–1.175B; total revenue $450–475M; adjusted EBITDA >$300M.
Ironwood (Nasdaq: IRWD) presented LANDMARK survey and clinical updates at DDW 2026 highlighting unmet needs in short bowel syndrome with intestinal failure (SBS-IF).
HCPs prioritized reducing days on TPN (46.4%) and cited central line infections (59.8%) and catheter-related challenges (48.2%) as major burdens. Apraglutide long-term safety remained consistent; linaclotide showed tolerability and symptom benefit across analyses.
Summary not available.
Ironwood Pharmaceuticals (Nasdaq: IRWD) will present LANDMARK survey findings and STARS long-term safety data for apraglutide at Digestive Disease Week® 2026, May 2–5 in Chicago. Presentations also cover linaclotide analyses in IBS-C, CIC and pediatric functional constipation, highlighting HCP perspectives on TPN burden in SBS-IF.